Akademik Veri Yönetim Sistemi
Retina-Vitreus, cilt.19, sa.2, ss.90-96, 2011 (Scopus)
Purpose: To evaluate the functional and anatomical results of different therapeutic approaches in acute, chronic, and recurrent central serous chorioretinopathy (CSC). Materials and Methods: Ninety-four eyes of 72 patients with the diagnosis of CSC between May 2000 and 2010 were studied retrospectively. Ophthalmic examination, fluorescein angiography (FA), fundus autofluorescence imaging, and optical coherence tomography (OCT) were performed at the initial examination and control visits. Indocyanine green angiography was performed in some cases. The main outcomes of this study were the improvement in logMar best corrected visual acuity (BCVA) and the regression of subretinal fluid in OCT. The mean follow-up was 16.6 months. Results: Of the 72 patients, 47 (65.3%) were male and 25 (34.7%) were female. The mean age was 45.5 years. There was bilateral involvement in 22 (30.5%) patients. Twenty-eight (29.8%) of the 94 eyes had acute, 43 (45.7%) chronic, and 23 (24.5%) recurrent CSC. Sixty eyes (63.8%) were observed without any treatment, 6 eyes (6.4%) underwent thermal laser photocoagulation, 9 eyes (9.5%) had PDT, and 18 eyes (19.1%) had intravitreal ranibizumab injection. In one eye (1.1%) combined treatment with PDT and intravitreal anti-VEGF injection was administered. At the initial examination, the mean BCVA was 0.3 logMAR (0-1.1), and the mean height of subretinal fluid (SRF) was 173.6 mm (0-571). During the last visit, the mean BCVA was 0.2 logMAR (0-1.2) and the mean height of SRF was 60.7 mm (0-378). Although there was an increase in visual acuity in all groups, it was not statistically significant. The SRF decreased in all groups, but there was a statistically significant difference only in the observation and injection group. Conclusion: Different treatment modalities can be performed in central serous chorioretinopathy according to the type and the duration of the disease. In our study, satisfactory anatomical and functional results were obtained in the anti-VEGF injection group. Studies with larger series and longer follow-up are needed to support our results.